The proceeds are being used to commercialize in Europe the company’s patented m.pulse device designed to treat chronic heart failure (CHF), non-surgically, in a patient’s home.
Cardiola’s m.pulse device, based on Muscular CounterPulsation technology, is approved in Europe for treating CHF as a nonsurgical, at-home therapy. In addition to helping patients, m.pulse with Muscular CounterPulsation offers cardiologists an additional source of revenue, the company said.